CART Cell Toxicities: New Insight into Mechanisms and Management

T cells genetically engineered with chimeric antigen receptors (CART) have become a potent class of cancer immunotherapeutics. Numerous clinical trials of CART cells have revealed remarkable remission rates in patients with relapsed or refractory hematologic malignancies. Despite recent clinical suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahid, Anas, Siegler, Elizabeth L., Kenderian, Saad S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Atlantis Press 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785104/
https://www.ncbi.nlm.nih.gov/pubmed/33409484
http://dx.doi.org/10.2991/chi.k.201108.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785104/
https://www.ncbi.nlm.nih.gov/pubmed/33409484
http://dx.doi.org/10.2991/chi.k.201108.001

Ejemplares similares